Spero Therapeutics Announces Third Quarter 2018 Financial Results and Pipeline Overview
November 08, 2018 16:10 ET
|
Spero Therapeutics, Inc.
Pipeline rapidly advancing with three clinical trials planned to initiate by early 2019, including a SPR994 Phase 3 initiation around year-end 2018 CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE)...
Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial
November 05, 2018 08:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR206
October 11, 2018 08:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Announces Positive SPR994 Phase 1 SAD/MAD Final Results
September 27, 2018 16:01 ET
|
Spero Therapeutics, Inc.
Multiple ascending dose clinical data supports advancement of 600 mg TID dose for pivotal Phase 3 clinical trial, planned for initiation around year-end 2018600 mg dose provides greater drug exposure...
Spero Therapeutics Announces Presentations at IDWeek 2018
September 25, 2018 16:01 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics to Present at the Cantor Global Healthcare Conference in October
September 19, 2018 08:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics to Present New Data for SPR994 and SPR206 at ESCMID/ASM 2018 Conference
August 28, 2018 08:00 ET
|
Spero Therapeutics, Inc.
Highlights include eleven presentations covering SPR994’s pharmacokinetics and pharmacodynamics, SPR206’s broad spectrum of activity and favorable toxicology, and urinary tract infection epidemiology ...
Spero Announces Appointment of John C. Pottage, Jr., MD to its Board of Directors
August 14, 2018 08:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Second Quarter 2018 Financial Results and Pipeline Overview
August 09, 2018 16:10 ET
|
Spero Therapeutics, Inc.
Pipeline continues to advance following recent positive data from SPR994 and Potentiator Platform; SPR994 Phase 3 initiation on-track to initiate around year-endRecent Follow-on Offering and BARDA...
Spero Awarded up to $54 Million by BARDA and DTRA to Support SPR994 Development
July 16, 2018 06:59 ET
|
Spero Therapeutics, Inc.
Inter-agency collaboration among BARDA, DTRA, USAMRIID and Spero to fund further clinical development of product candidate SPR994Planned pivotal Phase 3 trial of SPR994 on track to initiate around...